Search

DexCom Inc

Geschlossen

BrancheGesundheitswesen

91.02 -1.18

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

90.86

Max

92.56

Schlüsselkennzahlen

By Trading Economics

Einkommen

50M

249M

Verkäufe

117M

1.3B

KGV

Branchendurchschnitt

35.083

57.371

EPS

0.7

Gewinnspanne

19.039

Angestellte

11,000

EBITDA

52M

389M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+0.97% upside

Dividenden

By Acuity

Nächstes Ergebnis

29. Okt. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

5.2B

33B

Vorheriger Eröffnungskurs

92.2

Vorheriger Schlusskurs

91.02

DexCom Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

21. Aug. 2026, 19:36 UTC

Social Media

Dexcom Inc shares are higher as $1.6 million in call options signals bullish investor sentiment. The stock has recovered from earlier session lows.

20. Aug. 2026, 19:36 UTC

Dexcom Inc shares are higher today, continuing a three-session upward trend. The stock has fluctuated within a narrow range during regular trading hours.

19. Aug. 2026, 19:41 UTC

Dexcom Inc shares are higher Wednesday, pulling back from an early peak. The stock is trading with unusually high volume and remains above its 20-day moving average.

18. Aug. 2026, 19:16 UTC

Dexcom Inc shares are higher today, reflecting positive market sentiment despite no specific news. The stock remains above its 20-day moving average.

17. Aug. 2026, 19:46 UTC

Dexcom Inc's shares are lower today, continuing a decline since Friday's close. No specific news has been identified to explain the price movement.

14. Aug. 2026, 19:16 UTC

Dexcom Inc shares are lower today, continuing a decline since Thursday's close amid broader market caution following an unexpected drop in U.S. retail sales.

13. Aug. 2026, 19:26 UTC

Dexcom Inc shares are higher today, despite an earlier pullback. The stock's advance contrasts with a broader market decline since the session's start.

12. Aug. 2026, 19:36 UTC

Dexcom Inc shares are higher amid broader market optimism following inflation data. The core Consumer Price Index showed a modest increase, aligning with forecasts.

11. Aug. 2026, 23:26 UTC

Dexcom Inc shares are trading lower in after-market hours. Broader market trends and cautious investor sentiment may be influencing this price movement.

10. Aug. 2026, 20:02 UTC

Dexcom Inc shares are higher today, continuing an upward trend since Friday. The move occurs amid recent labor market data influencing investor sentiment.

7. Aug. 2026, 23:46 UTC

Dexcom Inc shares are higher in after-market hours, continuing recent positive momentum. The stock remains well above its 20-day moving average.

5. Aug. 2026, 19:51 UTC

News

Dexcom shares are declining amid negative sentiment in the insulin sector following Podd's revenue growth forecast cut. Broader economic data also influences cautious market sentiment.

4. Aug. 2026, 19:56 UTC

Dexcom Inc. shares are lower today, pulling back after reaching a session high. The broader market benefits from a significant decline in crude oil prices.

3. Aug. 2026, 20:02 UTC

News
Social Media

Dexcom Inc. shares are higher following strong Q2 results and raised revenue guidance to $5.22 billion. Canaccord increased its price target to $90.

31. Juli 2026, 20:04 UTC

News
Social Media

Dexcom Inc. shares are higher following analyst upgrades and strong earnings, with second-quarter revenue of $1.31 billion exceeding expectations and guidance raised to $5.22 billion.

30. Juli 2026, 23:51 UTC

News
Social Media

Dexcom reported second-quarter revenue of $1.308 billion and adjusted EPS of $0.70, raising its fiscal year 2026 revenue guidance, with shares trading higher in after-market hours.

29. Juli 2026, 23:41 UTC

Dexcom Inc is trading higher in after-market hours, supported by overall market strength. The asset remains above its 20-day moving average.

28. Juli 2026, 20:06 UTC

News

Dexcom shares rise after UBS initiated coverage with a Buy rating. The stock is advancing since Monday's close of $73.37 amid positive sentiment in the Health Care Equipment sector.

27. Juli 2026, 19:06 UTC

News

Dexcom Inc. gains Health Canada approval for its Dexcom G7 continuous glucose monitoring system, boosting marketability and user adoption amid positive analyst sentiment.

24. Juli 2026, 15:22 UTC

Dexcom Inc's shares are higher today, driven by gains in the Health Care Equipment sub-sector. No specific company news was identified for the movement.

22. Juli 2026, 20:01 UTC

Dexcom Inc. shares are lower today, continuing a decline since Tuesday. Earlier, the stock briefly rose before pulling back.

21. Juli 2026, 19:26 UTC

Dexcom Inc is trading lower, continuing a trend of three consecutive declines. The stock reached a session low earlier today before a slight recovery.

20. Juli 2026, 19:22 UTC

Dexcom Inc shares are lower amid broader market declines and rising Treasury yields. The stock remains near the upper end of its one-month trading range.

Peer-Vergleich

Kursveränderung

DexCom Inc Prognose

Kursziel

By TipRanks

0.97% Vorteil

12-Monats-Prognose

Durchschnitt 93.24 USD  0.97%

Hoch 105 USD

Tief 82 USD

Basierend auf 19 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für DexCom Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

19 ratings

18

Buy

1

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über DexCom Inc

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
help-icon Live chat